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ABSTRACT 
Survivin is a member of the apoptosis inhibitor protein family and its polymorphisms may lead to susceptibility to 
cancer. The aim of this study was to investigate the possible association of c.-31G>C (rs9904341), c.454G>A 
(rs2071214), c.*148T>C (rs2239680) and c.*571T>C (rs1042489) polymorphisms of survivin gene with prostate 
cancer risk and provide some justification using in silico analysis. The 157 men with prostate cancer and 145 
healthy controls were included in a case-control study. The studied polymorphisms were genotyped using PCR-
RFLP method. An in silico approach was employed to show the possible effects of the polymorphisms on the 
survivin gene function. The study revealed that there are significant associations between c.-31CC genotype (OR= 
2.29, 95 % CI= 1.20-4.37, p= 0.012), c.-31C allele (OR= 1.62, 95 % CI= 1.17-2.26, p= 0.004), c.454AG genotype 
(OR= 2.03, 95 % CI= 1.02-4.04, p= 0.043), and c.*148C allele (OR= 1.49, 95 % CI= 1.04-2.15, p= 0.031) with 
prostate cancer. Using stratified analysis, we found also significant effects of age distribution on the association 
of c.-31G>C with prostate cancer risk (OR= 2.10, 95 % CI= 1.08-4.10, p= 0.030). Also as a preliminary study, it 
was shown that smoking status has significant effects on the association of c.-31G>C (OR= 1.94, 95 % CI= 1.08-
3.49, p= 0.027) and c.*148T>C (OR= 2.60, 95 % CI= 1.47-4.60, p= 0.001) polymorphisms with prostate cancer 
risk. Finally, in silico analysis revealed that c.-31G>C, which is located in a CpG island of the promoter may 
change transcriptional regulation of survivin gene and c.454G>A and *148T>C could affect protein structure and 
possible miRNA interaction with 3'-UTR of survivin transcript respectively. According to the results, c.-31G>C, 
c.454G>A, and c.*148T>C polymorphisms could be genetic risk factors for prostate cancer in an Iranian popula-
tion. However, further studies with larger sample size and different ethnicities are required to obtain more com-
prehensive results. 
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INTRODUCTION 
Prostate cancer is one of the common 
form of malignancies in men around the 
world (Schröder and Roobol, 2009). The oc-
currence of this cancer is increasing because 
of some exogenous and endogenous factors, 
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including smoking, job-related contacts to 
chemical compounds and chronic infectious 
diseases (Grönberg, 2003). Also, genetic fac-
tors play an important role in the susceptibil-
ity to prostate cancer (Mendiratta and Febbo, 
2007). Folate metabolism and apoptosis are of 
the key pathways, which are involved in the 
prostate cancer development and progression. 
Therefore, genetic variations in these path-
ways may influence the prostate cancer risk in 
different individuals and populations (Ho et 
al., 2011). 
Survivin is an apoptosis inhibitor and 
plays a negative regulatory role in this cellular 
event. It suppresses apoptosis progression by 
inhibition of the initiator caspase 9 and exe-
cutioner caspases 3 and 7 (Kotipatruni et al., 
2012). Also, survivin acts as an essential reg-
ulator of cell division especially in G1 to S 
transition of the cell cycle. Its expression in 
many tissues is limited but it is highly ex-
pressed in cancer cells, which suggests the di-
rect role of survivin in tumorigenesis (Eslami 
et al., 2016).  
The survivin gene, also called BIRC5, lo-
cates on chromosome 17 (17q25.3) and its en-
coded protein contains a BIR (Baculoviral 
IAP Repeat) domain (Altieri, 2001). Given 
the role of survivin in the carcinogenesis, so 
the varieties in this gene should be considered 
as potential markers for the diagnosis of can-
cer (Yang et al., 2009; Zhu et al., 2013). There 
is a common single nucleotide polymorphism 
(SNP) in the promoter region of survivin gene 
(c.-31G>C, rs9904341), which is located in 
the CDE/CHR repressor element and may re-
sult in the overexpression. Evidences ob-
tained from previous examines have shown 
that this polymorphism is associated with a 
variety of cancers such as colorectal and gas-
tric cancers (Qin et al., 2014), and nasopha-
ryngeal carcinoma (Chen et al., 2013). Also, 
it is reported that the SNP have an effect on 
age of onset of ovarian cancer (Han et al., 
2009). Moreover, there are two functional 
SNPs in the 3’-UTR of survivin (c.*571T>C, 
rs1042489; and c.*148T>C, rs2239680), 
which may alter post-transcriptional regula-
tion of the gene (Shi et al., 2012). It’s reported 
that carriers of the minor allele of c.*571T>C 
among breast cancer patients have a worse 
survival compared with the major homozy-
gotes. Also, it is shown that c.*148T>C may 
increase individual susceptibility to lung can-
cer probably by attenuating the interaction be-
tween miR-335 and survivin mRNA (Zu et 
al., 2013). Further, there is a missense transi-
tion, c.454G>A (rs2071214), on exon 6 of 
survivin, which results in p.Glu152Lys substi-
tution and may affect protein structure and 
function. A meta-analysis claimed that this 
SNP seemed to be associated with an in-
creased tumor risk in Asians (Zhu et al., 2013) 
and another study reported its association 
with familial breast cancer risk (Kabisch et 
al., 2015). In this study, at first we investi-
gated the association of survivin gene poly-
morphisms c.-31G>C, c.454G>A, 
c.*148T>C and c.*571T>C with prostate can-
cer and then, an in silico analysis was done to 
provide possible justification for the associa-
tion results. 
 
MATERIALS AND METHODS 
Subjects 
In a case-control study, 157 patients with 
prostate cancer and 145 age-matched healthy 
controls were randomly included. Case sub-
jects were recruited from prostate cancer pa-
tients admitted to oncology department of 
Shahid Beheshti hospital (Kashan, Iran) be-
tween 2014 and 2015. Prostate cancer was 
confirmed by elevated PSA serum levels 
(>2.5 ng/ml), digital rectal examination 
(DRE), and histopathology results. The 
Gleason score of patients was evaluated by a 
pathologist using the Gleason scoring system. 
Patients with other malignancies were ex-
cluded from this study. The individuals refer-
ring to the hospital for routine check-up ex-
amination who had PSA levels <2.5 ng/ml 
and/or normal DREs were included as control 
group. The subjects with symptoms and signs 
of any malignancy and family history of can-
cer were excluded from the control group. Af-
ter obtaining signed informed consent, 2 ml 
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blood was taken from all subjects and pre-
served in CBC tubes at -20° C for further us-
ages. Research protocols were approved by 
medical ethic committee of research council 
of Kashan University of Medical Sciences at 
Aug. 2014 (Ref no. IR.KAUMS.REC.1395.92). 
 
DNA extraction and SNPs genotyping 
Genomic DNA was isolated from periph-
eral blood samples using salting-out proce-
dure. The genotypes of c.-31G>C, c.454G>A, 
c.*148T>C and c.*571T>C polymorphisms 
of survivin gene were determined by PCR-
RFLP method. Primers around the SNPs were 
designed by utilizing Oligo7 software. The 
specific primers sequences are listed in Table 
1. PCR was carried out in a total volume of 
25 µl consisting of 2.5 µl of 10X PCR buffer, 
0.35 µM each of the sense and antisense pri-
mers, 0.75 µl of 50 mM dNTPs mixture, 2 
units of Taq DNA polymerase, and 50 ng of 
genomic DNA (all of PCR components were 
purchased from CinnaGen Co., Tehran, Iran). 
The PCR was done in a peqSTAR thermal cy-
cler system (PeqLab, Erlangen, Germany) us-
ing the following conditions: initial denatura-
tion at 94°C for 5 min, followed by 35 repeti-
tive cycles of denaturation at 9 °C for 45 sec, 
annealing at 60 °C (for c.-31G>C), 57 °C (for 
c.454G>A), 58 °C (for c.*148T>C) and 56 °C 
(for c.*571T>C) for 45 sec, and polymeriza-
tion at 72 °C for 40 sec, and a final polymeri-
zation at 72 °C for 7 min. PCR products of the 
SNPs c.-31G>C, c.454G>A, c.*148T>C and 
c.*571T>C were treated by EcoO109I, SacII, 
AvaII, MspI restriction enzymes, respectively. 
After incubation of EcoO109I and MspI enzy-
matic mixtures at 37 °C for 16 hours, they 
were electrophoresed onto 1 % agarose gels 
and visualized by GreenView safe staining 
(Applied BioProbes Co., USA). But, SacII 
and AvaII enzymatic mixtures were electro-
phoresed onto 8 % polyacrylamide gels and 
visualized by silver nitrate (AgNO3) staining. 
About c.-31G>C polymorphism, the digested 
samples showed three different patterns: gen-
otype GG, with 269- and 126-bp fragments, 
genotype CC with 395-bp fragment and gen-
otype GC with 395-, 269-, and 126-bp frag-
ments; given to c.454G>A transition: geno-
type GG with 100- and 22-bp fragments, gen-
otype AA with 100-bp fragment, and geno-
type AG with 122-, 100-, and 22-bp frag-
ments; concerning c.*148T>C polymor-
phism: genotype CC with 121- and 21-bp 
fragments, genotype TT with 142-bp frag-
ment, and genotype TC with 142-, 121-, and 
21-bp fragments. With regard to c.*571T>C 
polymorphism, genotype CC, with 297- and 
179-bp fragments, genotype TT with 476-bp 
fragment and genotype CT with 476-, 297-, 
and 179-bp fragments. Finally, DNA direct 
sequencing was used to approve the PCR-
RFPL procedures. For this purpose, one sam-
ple from each genotype was sequenced in Bi-
oneer Co. (Korea) using an automated DNA-
sequencing.  
 
 
Table 1: Primer sequences and polymerase chain reaction conditions 
SNP (rs no.) Primer sequence  (5’→3’) Product 
size  
Restriction 
enzyme 
c.-31G>C 
(rs9904341) 
F1: 5’- ACAGGCGTGAGCCACTGCACCC 395-bp EcoO109I 
R1: 5’- AGGCGCAGCCCTCCAAGAAGGG 
c.454G>A  
(rs2071214) 
F2: 5’- AGAAAGAATTTGAGGAAACCGC 122-bp SacII 
R2: 5’- AAACCCTGGAAGTGGTGCAG 
c.*148T>C  
(rs2239680) 
F3: 5’- AAATTAGATGTTTCAACTGTGGTC 142-bp AvaII 
R3: 5’- CAAAACAGCAAAAATGAGCC 
c.*571T>C  
(rs1042489) 
F4: 5’- GCTTACCAGGTGAGAAGTGAGG 476-bp MspI 
R4: 5’- GTATCTGCCAGACGCTTCCTATC 
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In silico analysis 
F-SNP database (http://comp-
bio.cs.queensu.ca/F-SNP/), which provides 
valuable information about the effects of 
SNPs (Lee and Shatkay, 2007) was used for 
discovering the possible effects of the c.-
31G>C SNP on survivin-gene function. Also, 
PNImodeler server (http://165.246.44.34/pni-
modeler/) that predicts protein-binding sites 
in a DNA sequence (Im et al., 2015) was used 
to evaluate F-SNP database report and to de-
termine possible effects of c.-31G>C SNP on 
protein binding sites in survivin promoter se-
quence. Considering that G to C transversion 
in promoter region may affect methylation 
statues of a CpG island in a regulatory se-
quence we used DataBase of CpG islands and 
Analytical Tool: DBCAT (Kuo et al., 2011) 
to identify if -31G>C locates in a CpG island 
(http://dbcat.cgm.ntu.edu.tw/). Also, the ef-
fects of c.454G>A exonic polymorphism on 
the structure and function of protein were 
evaluated by some bioinformatics tools. For 
example, hydrophobicity and average flexi-
bility of the protein was evaluated by ExPASy 
web server. Effect of c.454G>A polymor-
phism on secondary structure was evaluated 
by SOPMA secondary structure prediction 
method (Sapay et al., 2006). The SNAP soft-
ware was used to evaluate the overall effect of 
c.454G>A polymorphism on the function of 
survivin (Bromberg and Rost, 2007). The 
miRNA SNP ver2.0 database was employed 
for assessment of miRNA interaction with 3'-
UTR of survivin mRNA after c.*148T>C sub-
stitution (Gong et al., 2012).  
 
Statistical analysis  
An independent t-test was used for analy-
sis of numerical variables. Hardy-Weinberg 
equilibrium (HWE) was calculated for both 
case and control groups. A binary logistic re-
gression was used to estimate odd ratios 
(ORs) with a 95 % confidence interval (CI). 
Differences in the frequencies of alleles and 
genotypes between the case and control 
groups were assessed by a χ2 test. The p-val-
ues less than 0.05 were considered as statisti-
cally significant. All of these statistical anal-
yses were performed by the SPSS version 19 
statistical software package (SPSS, Inc, Chi-
cago, Illinois). 
 
RESULTS 
Characteristics of the study population 
Some clinical and demographic details of 
study subjects are presented in Table 2. There 
were no statistically significant differences 
for age, body mass index (BMI), and status of 
smoking between cases (mean age of 64.90 ± 
12.48, mean BMI of 23.25 ± 2.77, and 62.42 
% of ever smoking) and controls (mean age of 
66.69 ± 7.77, mean BMI of 23.51 ± 2.58, and 
71.03 % of ever smoking). Additionally, PSA 
level, and Gleason score were listed in Table 
2. 
Table 2: Clinical and demographic details of study subjects 
Variables Case (n= 157) Control (n=145) P value 
Age (years)  
Range 42-84 52-88  
Mean ± SD 64.90 ± 12.48 66.69 ± 7.77 0.139 
BMI (kg/m2)  
Mean ± SD 23.25 ± 2.77 23.51 ± 2.58 0.409 
Total PSA (ng/ml)    
Mean ± SD 107.08 ± 58.85 1.24 ± 0.74 <0.0001 
Smoking  
Yes 98 103 0.113 
No 59 42  
Gleason grade  
<7 42 - - 
7 38 - - 
>7 77 - - 
BMI: Body mass index, PSA: Prostate-specific antigen; SD: Standard deviation
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Associations of survivin gene  
polymorphisms with prostate cancer  
The allele and genotype frequencies of c.-
31G>C, c.454G>A, c.*148T>C, and c.*571T>C 
polymorphisms are summarized in Table 3. In 
the case of c.-31G>C polymorphism, the fre-
quencies of GG, GC, and CC genotypes in 
control group are 47.59 %, 37.93 %, and 
14.48 %, respectively while these percentages 
in case group are 33.76 %, 42.67 %, and 23.57 
%, respectively. Statistical analysis revealed 
that GC genotype does not increase the risk of 
prostate cancer (OR: 1.59, % CI= 0.96-2.63, 
p= 0.074). But, there was a significant associ-
ation between homozygous CC and prostate 
cancer in our study population (OR= 2.29, 95 
% CI= 1.20-4.37, p= 0.012). Also, carriers of 
C allele (GC+CC) were at a high risk for pros-
tate cancer (OR= 1.78, 95 % CI= 1.12-2.83, 
p= 0.015). Allele analysis revealed that C al-
lele is a risk factor for prostate cancer (OR: 
1.62, % CI= 1.17-2.26, p= 0.004). Concerning 
c.454G>A transition, heterozygote (AG) gen-
otype was associated with risk of prostate 
cancer (OR= 2.03, 95 % CI= 1.02-4.04, p= 
0.043). Furthermore, there was a significant 
association between carriers of G allele 
(AG+GG) and prostate cancer risk (OR= 
1.96, 95 % CI= 1.01-3.84, p= 0.048). Given 
to c.*148T>C transition, we found that carri-
ers of C allele (TC+CC) were at a high risk 
for prostate cancer (OR= 1.62, 95 % CI= 
1.03-2.56, p= 0.037). Also there was a signif-
icant association between C allele and pros- 
 
 
Table 3: Genotype and allele frequencies of c.-31G>C, c.454G>A, c.*148T>C and c.*571T>C polymor-
phisms 
Genotype/ 
Allele 
No. and Percentage OR (95 % CI) P 
Case (n=157) Control (n=145) 
A) c.-31G>C 
GG 53 (33.76 %) 69 (47.59 %) - - 
GC 67 (42.67 %) 55 (37.93 %) 1.59 (0.96-2.63) 0.074 
CC 37 (23.57 %) 21 (14.48 %) 2.29 (1.20-4.37) 0.012 
GC+CC 104 (66.24 %) 76 (52.41 %) 1.78 (1.12-2.83) 0.015 
G 173 (55.10 %) 193 (66.55 %) - - 
C 141 (44.90 %) 97 (33.45 %) 1.62 (1.17-2.26) 0.004 
B) c.454G>A 
AA 128 (81.53 %) 130 (89.66 %) - - 
AG 28 (17.83 %) 14 (09.66 %) 2.03 (1.02-4.04) 0.043 
GG 1 (00.64 %) 1 (00.68 %) 1.02 (0.06-16.41) 0.991 
AG+GG 29 (18.47 %) 15 (10.34 %) 1.96 (1.01-3.84) 0.048 
A 284 (90.45 %) 274 (94.48 %) - - 
G 30 (09.55 %) 16 (05.52) 1.81 (0.96-3.39) 0.065 
C) c.*148T>C 
TT 71 (45.22 %) 83 (57.24 %) - - 
TC 76 (48.41 %) 58 (40.00 %) 1.53 (0.96-2.44) 0.073 
CC 10 (06.37 %) 4 (02.76 %) 2.92 (0.88-9.72) 0.080 
TC+CC 86 (54.78) 62 (42.76 %) 1.62 (1.03-2.56) 0.037 
T 218 (69.43 %) 224 (77.24 %) - - 
C 96 (30.57 %) 66 (22.76 %) 1.49 (1.04-2.15) 0.031 
D) c.*571T>C 
TT 88 (56.05 %) 91 (62.76 %) - - 
TC 53 (33.76 %) 43 (29.65 %) 1.27 (0.77-2.10) 0.339 
CC 16 (10.19 %) 11 (07.59 %) 1.50 (0.66-3.42) 0.330 
TC+CC 69 (43.95 %) 54 (37.24 %) 1.32 (0.83-2.10) 0.236 
T 229 (72.93 %) 225 (77.59 %) - - 
C 85 (27.07 %) 65 (22.41 %) 1.28 (0.89-1.86) 0.186 
OR: Odds Ratio, CI: Confidence Interval 
Significant differences between the case and control groups are bolded 
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tate cancer risk (OR= 1.49, 95 % CI= 1.04-
2.15, p= 0.031). With regard to the 
c.*571T>C transition, there was no signifi-
cant association of TC (OR= 1.27, 95 % CI= 
0.77-2.10, p= 0.339) and CC (OR= 1.50, 95 
% CI= 0.66-3.42, p= 0.330) genotypes with 
prostate cancer risk. In addition, we found no 
significant association between c.*571T>C 
transition and prostate cancer in C vs. T (OR= 
1.28, 95 % CI= 0.89-1.86, p= 0.186) and 
TC+CC vs. TT (OR= 1.32, 95 % CI= 0.83-
2.10, p= 0.236) genetic models. 
 
Stratified analysis 
As a preliminary study, the associations of 
the four survivin gene polymorphisms with 
risk of prostate cancer were assessed by strat-
ified analysis via age, BMI, and smoking sta-
tus. When the c.-31G>C polymorphism in 
combination with age was studied in relation 
to prostate cancer risk, a significant associa-
tion was observed in a dominant model (Table 
4). When GG genotype with age less than 69 
years was considered as reference, carriers of 
C allele who were younger than 65 years 
showed a significant increased risk for pros-
tate cancer (OR= 2.10, 95 % CI= 1.08-4.10, 
p= 0.030). Moreover, after stratifying of anal-
ysis by smoking status, we found that there 
were significant associations between c.-
31G>C (OR= 1.94, 95 % CI= 1.08-3.49, p= 
0.027) and c.*148T>C (OR= 2.60, 95 % CI= 
1.47-4.60, p= 0.001) polymorphisms and 
prostate cancer in smoker subjects (Table 4). 
Additionally, no significant associations were 
observed between the c.454G>A and 
c.*571T>C and risk of prostate cancer in the 
stratified analysis (data not shown). 
 
In silico analysis 
F-SNP showed that rs9904341-SNP may 
change transcriptional regulation of survivin 
gene (Table 5). PNImodeler server predicted 
that the rs9904341-SNP alters binding nucle-
otides around SNP in both forward and revers 
strands of promoter DNA (Figure 1). DBCAT 
showed that in survivin gene BIRC5, there is 
a CpG island, which starts from 73721557 
and ends in 73722484 nucleotide (Figure 2). 
The SNP position in the sequence is 
73721963 and it occurs in BIRC5-gene CpG 
Island. With regard to c.454G>A SNP, we 
found that this polymorphism results in lysine 
to glutamate substitution at codon 152 
(Glu152Lys).  Bioinformatics  data  revealed 
 
 
Table 4: Stratified association analysis between survivin gene polymorphism and prostate cancer risk 
Variables c.-31G>C OR 
(95 % CI) 
P c.*148T>C OR 
(95 % CI) 
P 
(Cases/ 
Controls) 
(Cases/ 
Controls) 
CC+GC GG CC+TC TT 
Age, year         
൑	69 73/48 21/29 2.10  
(1.08-4.10) 
0.030 54/35 40/42 1.62  
(0.88-2.97) 
0.119 
> 69 31/28 32/40 1.38  
(0.69-2.76) 
0.357 32/27 31/41 1.57  
(0.78-3.13) 
0.204 
BMI (kg/m2)         
൑	25 78/61 46/57 1.58  
(0.95-2.65) 
0.079 70/53 54/65 1.59  
(0.96-2.64) 
0.073 
> 25 26/15 7/12 2.97  
(0.96-9.18) 
0.059 16/9 17/18 1.88  
(0.66-5.39) 
0.239 
Smoking  
status 
        
No 34/18 25/24 1.81  
(0.81-4.04) 
0.145 24/21 35/21 0.69  
(0.31-1.52) 
0.354 
Yes 70/58 28/45 1.94  
(1.08-3.49) 
0.027 62/41 36/62 2.60  
(1.47-4.60) 
0.001 
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Table 5: F-SNP results 
SNP ID Functional Category Prediction Tool Prediction Result FS score  
rs9904341 transcriptional regulation TFSearch changed 0.268 
Consite changed 
GoldenPath exist 
 
Figure 1: PNImodeler server prediction. (+) and (–) signs represent probable binding and nonbinding 
site on DNA strand respectively. A) Depicts probable nucleotides that may interact with protein around 
G allele of rs9904341 both in forward and revers sequences of promoter. B) Represents probable pro-
tein binding site in promoter sequence when there is a C nucleotide in -31 position. 
 
 
 
Figure 2: DBCAT predicts CpG islands of survivin gene BIRC5. -31G>C transversion that is highlighted 
in the right section of this figure locates in a CpG island. 
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that this substitution reduces hydrophobicity 
and average flexibility of the protein at resi-
dues 148 to 156 (Figure 3). Also, it could gen-
erate a minor change in the secondary struc-
ture at the C-terminal of protein (Figure 3). 
Moreover, the data from SNAP web server re-
vealed that Glu152Lys substitution could be 
damaging for protein function (Score= 7; ex-
pected accuracy= 53 %). Finally, we evalu-
ated the effects of c.*148T>C transition on 
miRNA interaction with 3'-UTR of survivin 
mRNA by miRNA SNP ver2.0 server. Our 
data revealed that this substitution reduces the 
interaction of has-mir-335 with 3'-UTR of 
survivin transcript. This SNP could alter the 
interaction energy between has-mir-335 and 
3'-UTR from -19.30 to 0.0 kcal/mol (Table 6). 
 
 
Figure 3: Hydrophobicity, average flexibility and secondary structure of survivin after c.454G>A transi-
tion. The hydrophobicity (A) and average flexibility (B) of protein alter in residues 148 to 156. Secondary 
structure of alters at the c-terminal of the protein (C&C’). 
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Table 6: Results of miRNA SNP ver2.0 database 
SNP miRNA Energy 
change 
(kcal/mol) 
miRNA/SNP-target duplexes Ef-
fect 
rs2239680 
(c.*148T>C) 
hsa-miR-
335 
Wild: -19.30 
SNP: 0.00 
 
loss 
 
 
 
DISCUSSION 
In this study, we investigated the associa-
tion of four common polymorphisms of sur-
vivin gene (c.-31G>C, c.454G>A, c.*148T>C 
and c.*571T>C) with prostate cancer which 
followed by a bioinformatics analysis to pro-
vide possible justification for association re-
sults. The experiments revealed that there are 
significant associations between c.-31G>C, 
c.454G>A, and c.*148T>C polymorphisms 
and prostate cancer in the studied population. 
But, we did not find any significant associa-
tion between c.*571T>C transition and pros-
tate cancer frequency. According to our 
knowledge, this study is the second report 
which evaluates the association of survivin 
gene polymorphisms with prostate cancer risk 
(Chen et al., 2013). In addition, Chen et al. 
(2013) reported only the association of -
31G/C variant with prostate cancer in Chinese 
people. While we evaluated the association of 
four SNPs in survivin gene with prostate can-
cer risk in Iranian population. Also, some ep-
idemiological studies have been investigating 
the association of survivin gene c.-31G>C 
polymorphism with the other urinary tract 
cancers risk. For example, Kawata et al. 
(2011) and Jaiswal et al. (2012) reported that 
c.-31G>C transversion is associated with 
bladder cancer in Japanese and Indian popu-
lations, respectively. In addition, Qin et al. 
(2012) reported that this polymorphism is as-
sociated with renal cell cancer in Chinese 
population while Marques et al. (2013) re-
ported that this polymorphism is not associ-
ated with renal cell cancer in southern Euro-
pean population. The different results be-
tween these studies may arise from difference 
in cancer type or ethnicity. In the stratified 
analysis, we found significant effects of age 
distribution on the association of c.-31G>C 
and prostate cancer risk. Also, there were sig-
nificant effects of smoking status on the asso-
ciation of c.-31G>C and c.*571T>C polymor-
phisms with the cancer risk. These results 
show possible interactions among age and 
smoking status in the etiology of prostate can-
cer. 
Numerous genetic association studies 
have recognized many susceptibility variants, 
suggesting the main role of genetic factors in 
development of prostate cancer (Wiklund, 
2010). Then, considering the survivin gene 
mode of function and expression, it is not sur-
prising searching about the association of its 
variations with cancer frequency. Indeed, sur-
vivin is a tumor specific molecule, which in-
hibits caspase-9 activation and causes preven-
tion of apoptosis. Also, it has a role in tumor-
related angiogenesis (Eslami et al., 2016). 
The expression of survivin gene is elevated in 
embryonic tissues, whereas its expression is 
undetectable in differentiated tissues. How-
ever, this gene is overexpressed in several tu-
mors (Altieri, 2008) and there is a positive as-
sociation between the survivin overexpres-
sion and tumors grade (Duffy et al., 2007). In-
deed, according to the evidences, survivin 
could be one of the important diagnostic and 
prognostic biomarkers for monitoring of tu-
mor progressions (Ghadersohi et al., 2011). 
Single nucleotide polymorphism could 
change the gene expression pattern, mRNA 
structure and protein function (Ebrahimi et 
al., 2017; Karimian and Hosseinzadeh Co-
lagar, 2018; Teimouri et al., 2018). Numerous 
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evidences suggested that functional genetic 
polymorphisms could alter the survivin gene 
expression (Ambrosini et al., 1997). The sur-
vivin overexpression induced from functional 
SNPs may result in reduced apoptotic capac-
ity and increased tumor susceptibility (Qin et 
al., 2014). The c.-31G>C transversion can 
disrupt the binding site of CDE/CHR re-
pressor and subsequently increase the expres-
sion of survivin (Xu et al., 2004). Also, in 
vitro analysis revealed that c.-31C allele is 
more active transcriptionally rather than c.-
31G allele. Therefore, individuals with c.-
31CC genotype may have up-regulated levels 
of survivin gene (Jang et al., 2008). In addi-
tion, c.*148T>C is a key SNP, which could 
increase the expression of survivin in tumor 
tissues by changing the affinity of miRNA 
with 3’-UTR of the transcript (Zu et al., 
2013). 
Some recent publications showed that us-
ing in silico analysis could be a helpful ap-
proach to understand and interpret the poly-
morphism effect more specifically (Mazaheri 
et al., 2017; Soleimani et al., 2017). Here we 
provide an in silico approach to approve our 
experimental study as a novel part of our 
study. We utilized bioinformatics servers to 
predict the consequences of c.-31G>C, 
c.454G>A, and c.*148T>C SNPs in survivin 
gene function. F-SNP uses TFSearch and 
ConSite to predict the effects of SNPs on 
TFBS and UCSC Golden Path and Ensembl 
to retrieve annotated potential regulatory re-
gions like CpG islands. The FS score for c.-
31G>C was 0.268 and in this server higher 
score is assigned to already known disease-re-
lated SNPs than to neutral SNPs. F-SNP re-
ported that the c.-31G>C transversion causes 
to a transcriptional regulation change. Also, 
PNImodeler prediction revealed that -31G>C 
transversion changes pattern of probable pro-
tein binding sites in survivin promoter se-
quence around transversioned nucleotide that 
may alter transcription factor interactions 
with the promoter region and affects gene ex-
pression. As is depicted in the Figure 1, + sites 
that represent probable binding site on DNA 
strand is changed both in forward and revers 
strands of DNA. These events may affect 
gene expression since of alteration in tran-
scription factor interaction with promoter se-
quences. In addition, c.-31G>C SNP occurs in 
a CpG island (Figure 2) and any alteration in 
this sequence may affect methylation status of 
the promoter. Methylation of CpG Islands has 
been widely described as a mechanism asso-
ciated with gene expression regulation 
(Moarii et al., 2015) especially in prostate 
cancer (Massie et al., 2017). Also, SNPs that 
alter methylation pattern of promoter have 
been reported as important factor in gene ex-
pression differences between cells and tissues 
(Bell et al., 2011) and it is reported that pros-
tate cancer is influenced from such SNP types 
(Kloth et al., 2012). Also, we evaluated the ef-
fects of c.454G>A polymorphism on the 
structure of protein by in silico approach. We 
observed that some properties of the protein 
such as hydrophobicity, average flexibility, 
and secondary structure of protein changed 
after c.454G>A transition. These changes 
could alter folding and function of protein 
(Nicholls et al., 1991; Teng et al., 2010). 
Then, we assessed the effects of c.*148T>C 
substitution on the miRNA interaction with 
3'-UTR of survivin mRNA. We found that this 
substitution could reduce the interaction of 
has-mir-335 with 3'-UTR of survivin mRNA. 
Therefore, it may result in survivin overex-
pression and subsequently tumorigenesis (Zu 
et al., 2013). 
Since, the estimation of sample size based 
on some previous studies investigating the as-
sociation of survivin gene polymorphisms 
with urinary system cancers (Wang et al., 
2009; Jaiswal et al., 2012) revealed that our 
sample size is fairly adequate. For example, 
based on sample size of Wang et al. (2009) 
study, we estimated the sample size equal to 
144 subjects when α value and power consid-
ered as 0.05 and 0.8, respectively. But in the 
stratified analysis, we acknowledge the small 
sample size issue. Therefore, we considered 
our stratified analysis as a preliminary study. 
In addition, we estimated the optimized sam-
ple size of our study according to genotype 
frequencies with α value= 0.05 and power= 
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0.8 and we found that a sample size equal to 
500 subjects (including 250 cases and 250 
controls) is enough for this genetic associa-
tion study. 
In conclusion, c.-31G>C, c.454G>A, and 
c.*148T>C polymorphisms may be risk fac-
tors for prostate cancer susceptibility in an 
Iranian population. But, further studies with 
larger sample size (about 500 subjects) are re-
quired to achieve more accurate results. 
There are some limitations in this study 
which should be considered. Firstly, our small 
sample size is a great limitation of our study. 
Also, we did not evaluate the gene-gene inter-
actions in the case-control study. The current 
study is based on the identification method of 
the ‘one-step-clustering’. This approach has 
been reported that it might tend to be ‘passen-
ger signals’ instead of ‘drivers’, bury the 
‘real’ cancer gene and ignore the interaction 
of gene-gene, which made the results less ro-
bust and accurate. Moreover, we did not eval-
uate the effects of functional SNPs of survivin 
by in vitro approach. 
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